Tag: Novo obesity drug effectiveness
Novo’s New Obesity Drug: Modest Results and Psychiatric Side Effects Concerns
Novo Nordisk, a leading pharmaceutical company, recently released data from a Phase 2a trial of their new obesity drug candidate, monlunabant. This drug, which inhibits CB1 receptors and was acquired through Novo's purchase of...